Urteste names Christian Pangratz CEO effective Sept. 1, 2026

Urteste S.A. has appointed Christian Pangratz as chief executive officer, effective Sept. 1, 2026, as the company advances Panuri, its lead urine-based test for early pancreatic cancer detection. The move adds a life sciences executive with more than 25 years of experience and a record of licensing and M&A deals to the Polish diagnostics developer.

Why it matters: - Urteste is moving its leadership as the company pushes toward commercialization and partner discussions for its cancer-detection platform. - Christian Pangratz brings more than 25 years in life sciences, plus a history of licensing and M&A transactions that may help Urteste advance business development. - Panuri is in European clinical testing for pancreatic cancer, a disease with poor prognosis and high unmet diagnostic need.

What happened: - Urteste S.A. appointed Christian Pangratz as chief executive officer, effective 1 September 2026. - The appointment was made by Urteste’s Supervisory Board. - From that date, Urteste’s Management Board will consist of Christian Pangratz, Grzegorz Stefański and Tomasz Kostuch. - Urteste said Pangratz is an international life sciences executive with experience across biotechnology, specialty pharmaceuticals and platform technology companies in Europe, North America and Asia.

The details: - Pangratz has held CEO and other senior executive roles at venture capital-backed and publicly listed companies. - His background includes leading projects from preclinical development through clinical development. - Urteste said Pangratz has been involved in licensing and M&A transactions with a combined net present value of more than EUR 4.5 billion. - His career includes helping establish a partnership between Nektar Therapeutics and AstraZeneca valued at USD 1.5 billion. - He also led the sale of Activaero to Vectura for EUR 130 million. - Pangratz has raised more than EUR 32 million in equity financing, along with significant non-dilutive funding. - Urteste’s priority project is Panuri, a test in development for early detection of pancreatic cancer. - The first patient in Panuri’s European clinical study was enrolled in early June. - The study’s primary goal is to assess Panuri’s diagnostic performance for pancreatic cancer, with sensitivity and specificity among the primary endpoints. - Urteste says it has 13 prototype diagnostic tests targeting breast, brain, gastric, biliary tract, ovarian, bladder, endometrial, kidney, colorectal, lung, liver, pancreatic and prostate cancers. - Urteste says those cancers account for nearly 70% of all cancer-related deaths worldwide.

Between the lines: - Urteste is pairing a clinical-stage pipeline with a CEO who has deep dealmaking and financing experience. - That combination suggests the company is preparing for later-stage validation, outside partnerships and potential commercialization milestones. - Pangratz’s own comments pointed to commercialization, industry cooperation and value creation as near-term priorities. - Grzegorz Stefański framed the hire as especially relevant now that Panuri has entered multicentre clinical study in Europe.

What's next: - Pangratz is set to take over on 1 September 2026. - Urteste said work will continue on commercial validation of the technology and cooperation with potential industry partners. - Progress in the Panuri clinical study will be a key milestone to watch as the company moves toward potential commercialization.

The bottom line: - Urteste is bringing in a deal-focused life sciences executive as it tries to turn its urine-based cancer tests into a commercial platform.